^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr t(15;17)

    8d
    NCI-2023-03572: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2029 | Trial primary completion date: Dec 2026 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Chr t(15;17)
    |
    cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)
    22d
    QUATRO-APL: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P3, N=150, Recruiting, Quetzal Therapeutics
    New P3 trial
    |
    PML (Promyelocytic Leukemia)
    |
    Chr t(15;17)
    |
    Vesanoid (tretinoin) • arsenic trioxide
    26d
    Preliminary Effects of Benralizumab in an AML Cell Model with Promyelocytic Features Expressing IL-5R: An Exploratory Proof-of-Concept Study. (PubMed, Biomedicines)
    When interpreted together with the in silico analyses performed on AML patient datasets, these results support the rationale for future validation in APL-oriented models carrying the PML::RARα fusion, the disease-defining oncogenic driver generated by the t(15;17) translocation that blocks myeloid differentiation. However, the in silico and in vitro datasets were not formally integrated at the patient level, and these functional results should be considered exploratory.
    Journal
    |
    RARA (Retinoic Acid Receptor Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP8 (Caspase 8) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IL5 (Interleukin 5)
    |
    Chr t(15;17)
    2ms
    BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date • Tumor mutational burden
    |
    Chr t(15;17)
    |
    Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine
    2ms
    A Case of Acute Promyelocytic Leukemia with t(11;17)(q23.2;q21.2) Treated with Haploidentical Transplantation Using Post-Transplant Cyclophosphamide. (PubMed, Intern Med)
    He underwent haploidentical transplantation using post-transplant cyclophosphamide (PTCy) after conventional chemotherapy and maintained long-term remission. This case highlights the importance of a morphological diagnosis and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in APL with t(11;17)(q23.2;q21.2).
    Journal
    |
    ZBTB16 (Zinc Finger And BTB Domain Containing 16)
    |
    Chr t(15;17)
    |
    cyclophosphamide
    2ms
    NCI-2023-03572: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (clinicaltrials.gov)
    P1, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2027 --> Dec 2029
    Trial completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Chr t(15;17)
    |
    cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)
    2ms
    Primary Indolent Acute Promyelocytic Leukemia. (PubMed, Hematol Rep)
    Induction therapy with all-trans-retinoic acid and arsenic trioxide resulted in hematologic remission...Atypical clinical trajectories should prompt careful assessment of marrow morphology and immunophenotypic features. Continued characterization of such cases may refine diagnostic criteria and direct individualized approaches to therapy.
    Journal
    |
    TP53 (Tumor protein P53) • ETV6 (ETS Variant Transcription Factor 6)
    |
    TP53 mutation • Chr t(15;17)
    |
    arsenic trioxide
    2ms
    Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=178, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    RARA (Retinoic Acid Receptor Alpha) • CBFB (Core-Binding Factor Subunit Beta 2)
    |
    Chr t(15;17)
    |
    cytarabine • decitabine • daunorubicin • Starasid (cytarabine ocfosfate)
    2ms
    A Rare Case of Acute Promyelocytic Leukemia with ider(17)(q10)t(15;17)(q22;q21) and FLT3-ITD Mutation. (PubMed, Clin Lab)
    This case of APL with coexisting ider(17) and FLT3-ITD mutations exhibited an aggressive course and resistance to standard treatment. These findings suggest that such patients may require intensified therapeutic strategies and closer monitoring.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • Chr t(15;17)
    |
    idarubicin hydrochloride
    3ms
    Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent (clinicaltrials.gov)
    P2, N=28, Recruiting, University of California, Davis | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132 • Chr t(15;17)
    |
    Venclexta (venetoclax) • azacitidine • Rezlidhia (olutasidenib)
    4ms
    Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Chr t(15;17)
    |
    cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin)
    4ms
    French Registry of First-line Treatment of Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P=N/A, N=400, Active, not recruiting, Groupe Francophone des Myelodysplasies | Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Jul 2026 | Trial primary completion date: Oct 2020 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    RARA (Retinoic Acid Receptor Alpha)
    |
    Chr t(15;17)